These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. Enseleit F; Hürlimann D; Lüscher TF J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475 [TBL] [Abstract][Full Text] [Related]
24. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Ruschitzka FT; Lüscher TF Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622 [TBL] [Abstract][Full Text] [Related]
25. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone. Lüscher TF Basic Res Cardiol; 1993; 88 Suppl 1():15-24. PubMed ID: 8357330 [TBL] [Abstract][Full Text] [Related]
26. Endothelial function and bradykinin in humans. Hornig B; Drexler H Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844 [TBL] [Abstract][Full Text] [Related]
27. Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle. Lüscher TF; Yang Z Drugs; 1993; 46 Suppl 2():121-32. PubMed ID: 7512465 [TBL] [Abstract][Full Text] [Related]
28. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Mombouli JV Drugs; 1997; 54 Suppl 5():12-22. PubMed ID: 9429841 [TBL] [Abstract][Full Text] [Related]
29. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Hornig B; Arakawa N; Drexler H Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056 [TBL] [Abstract][Full Text] [Related]
31. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Higashi Y; Chayama K; Yoshizumi M Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):133-48. PubMed ID: 15853700 [TBL] [Abstract][Full Text] [Related]
37. [Role of the endothelium in the control of vascular motility: physiologic aspects and physiopathologic implications in cardiovascular diseases]. Limone P; Boeri E; Molinatti GM Minerva Med; 1993 Oct; 84(10):499-505. PubMed ID: 8247303 [TBL] [Abstract][Full Text] [Related]
38. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors]. Tschudi MR; Noll G; Lüscher TP Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890 [TBL] [Abstract][Full Text] [Related]
39. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. Landmesser U; Drexler H J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572 [TBL] [Abstract][Full Text] [Related]